Clinical Trial Eligibility Criteria Requirement
Item
subjects must meet the following eligibility requirements to be enrolled in the study.
boolean
C1516637 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
Age
Item
1. subject must be 18 years of age or older.
boolean
C0001779 (UMLS CUI [1])
Ovarian Carcinoma | Recurrent Endometrial Cancer | Lesion size | Lesion Quantity | Ultrasonography | Magnetic Resonance Imaging | X-Ray Computed Tomography
Item
2. subject must have known or strongly suspected ovarian carcinoma or recurrent endometrial carcinoma with at least one identifiable lesion > 1.5 cm as diagnosed by ultrasonography, mri, or ct.
boolean
C0029925 (UMLS CUI [1])
C0278802 (UMLS CUI [2])
C0449453 (UMLS CUI [3])
C0221198 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C0041618 (UMLS CUI [5])
C0024485 (UMLS CUI [6])
C0040405 (UMLS CUI [7])
Renal function
Item
3. subject must have good kidney function.
boolean
C0232804 (UMLS CUI [1])
Informed Consent
Item
4. subject must provide written informed consent prior to enrollment.
boolean
C0021430 (UMLS CUI [1])
Condition Present
Item
subjects must be excluded if any of the following conditions are present:
boolean
C0348080 (UMLS CUI [1,1])
C0150312 (UMLS CUI [1,2])
Pregnancy | Breast Feeding
Item
1. subject is pregnant or breastfeeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Study Subject Participation Status | Investigational New Drugs
Item
2. subject is simultaneously participating in another investigational drug study.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Clinical Study Follow-up Previous Completed
Item
3. subject has completed the follow-up phase of any previous study less than 30 days prior to enrollment in this study.
boolean
C3274571 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
Radionuclide Imaging Receive Unable
Item
4. subject is unable to tolerate conditions for radionuclide imaging.
boolean
C0034606 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
Radiopharmaceutical Interferes with Assessment Technetium 99m E folate peptide
Item
5. subject has been administered another radiopharmaceutical that would interfere with the assessment of technetium tc 99m ec20.
boolean
C0182638 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C1516048 (UMLS CUI [1,3])
C4042715 (UMLS CUI [1,4])